The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network
Open accessAbstract
Background and Aims: The coronavirus‐19 disease (COVID‐19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 virus, is associated with significant morbidity and mortality attributable to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Liver injury has been reported as a nonpulmonary manifestation of COVID‐19, but characterization of liver test abnormalities and their association with clinical outcomes is incomplete. Approach and Results: We conducted a retrospective cohort study of 1,827 patients with confirmed COVID‐19 who were hospitalized within the Yale‐New Haven Health System between March 14, 2020 and April 23, 2020. Clinical characteristics, liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time points (preinfection baseline, admission, and peak hospitalization), and hospitalization outcomes (severe COVID‐19, intensive care unit [ICU] admission, mechanical ventilation, and death) were analyzed. Abnormal liver tests were commonly observed in hospitalized patients with COVID‐19, both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%). Most patients with abnormal liver tests at admission had minimal elevations 1‐2× the upper limit of normal (ULN; AST 63.7%, ALT 63.5%, ALP 80.0%, and TBIL 75.7%). A significant proportion of these patients had abnormal liver tests prehospitalization (AST 25.9%, ALT 38.0%, ALP 56.8%, and TBIL 44.4%). Multivariate analysis revealed an association between abnormal liver tests and severe COVID‐19, including ICU admission, mechanical ventilation, and death; associations with age, male sex, body mass index, and diabetes mellitus were also observed. Medications used in COVID‐19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir, and tocilizumab) were associated with peak hospitalization liver transaminase elevations >5× ULN. Conclusions: Abnormal liver tests occur in most hospitalized patients with COVID‐19 and may be associated with poorer clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542
Clinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Sultan, S., Altayar, O., Siddique, S. M., Davitkov, P., Feuerstein, J. D., Lim, J. K., Falck-Ytter, Y., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.001 · Cited by 437
Self-citationRedd, W. D., Zhou, J. C., Hathorn, K. E., McCarty, T. R., Bazarbashi, A. N., Thompson, C. C., Shen, L., & Chan, W. W. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.045 · Cited by 313
Hajifathalian, K., Krisko, T., Mehta, A., Kumar, S., Schwartz, R., Fortune, B., Sharaiha, R. Z., Kaplan, A., Gonzalez, S., Skaf, D., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.010 · Cited by 150
Cited by
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Pathophysiological mechanisms of liver injury in COVID‐19
Nardo, A. D., Schneeweiss‐Gleixner, M., Bakail, M., Dixon, E. D., Lax, S. F., & Trauner, M. (2021) · Liver International · doi:10.1111/liv.14730 · Cited by 397
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell, M. J., Kawaguchi, N., Kondo, R., Sonzogni, A., Licini, L., Valle, C., Bonaffini, P. A., Sironi, S., Alessio, M. G., Previtali, G., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.050 · Cited by 111
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., et al. (2021) · Advanced Science · doi:10.1002/advs.202101222 · Cited by 88
Metadata
- Authors
- Hundt, M. A., Deng, Y., Ciarleglio, M. M., Nathanson, M. H., & Lim, J. K.
- Venue
- Hepatology
- Published
- 2020-10
- Volume
- 72
- Issue
- 4
- Pages
- 1169-1176
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3045742311
- Cited by
- 248
- References
- 8
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.